Blue Jet Healthcare Limited (BLUEJET) - Net Assets
Based on the latest financial reports, Blue Jet Healthcare Limited (BLUEJET) has net assets worth Rs13.60 Billion INR (≈ $147.07 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs16.41 Billion ≈ $177.49 Million USD) and total liabilities (Rs2.81 Billion ≈ $30.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Blue Jet Healthcare Limited balance sheet independence to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs13.60 Billion |
| % of Total Assets | 82.86% |
| Annual Growth Rate | 37.34% |
| 5-Year Change | 160.75% |
| 10-Year Change | N/A |
| Growth Volatility | 16.85 |
Blue Jet Healthcare Limited - Net Assets Trend (2020–2026)
This chart illustrates how Blue Jet Healthcare Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see BLUEJET stock market capitalisation.
Annual Net Assets for Blue Jet Healthcare Limited (2020–2026)
The table below shows the annual net assets of Blue Jet Healthcare Limited from 2020 to 2026. Also explore Blue Jet Healthcare Limited equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs13.60 Billion ≈ $147.07 Million |
+20.02% |
| 2025-03-31 | Rs11.33 Billion ≈ $122.54 Million |
+34.06% |
| 2024-03-31 | Rs8.45 Billion ≈ $91.41 Million |
+24.03% |
| 2023-03-31 | Rs6.81 Billion ≈ $73.70 Million |
+30.67% |
| 2022-03-31 | Rs5.22 Billion ≈ $56.40 Million |
+53.48% |
| 2021-03-31 | Rs3.40 Billion ≈ $36.75 Million |
+67.61% |
| 2020-03-31 | Rs2.03 Billion ≈ $21.93 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Blue Jet Healthcare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs346.93 Million | 2.55% |
| Other Components | Rs13.25 Billion | 97.45% |
| Total Equity | Rs13.60 Billion | 100.00% |
Blue Jet Healthcare Limited Competitors by Market Cap
The table below lists competitors of Blue Jet Healthcare Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FuelCell Energy Inc
NASDAQ:FCEL
|
$1.03 Billion |
|
Hbt Financial Inc
NASDAQ:HBT
|
$1.03 Billion |
|
Hunan Heshun Petroleum Co Ltd
SHG:603353
|
$1.03 Billion |
|
Ningbo Fujia Industrial Co Ltd
SHG:603219
|
$1.03 Billion |
|
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
|
$1.03 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
$1.03 Billion |
|
E2open Parent Holdings Inc
NYSE:ETWO
|
$1.03 Billion |
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
$1.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Blue Jet Healthcare Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 11,331,110,000 to 13,599,120,000, a change of 2,268,010,000 (20.0%).
- Net income of 2,478,160,000 contributed positively to equity growth.
- Dividend payments of 208,180,000 reduced retained earnings.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs2.48 Billion | +18.22% |
| Dividends Paid | Rs208.18 Million | -1.53% |
| Other Changes | Rs-1.97 Million | -0.01% |
| Total Change | Rs- | 20.02% |
Book Value vs Market Value Analysis
This analysis compares Blue Jet Healthcare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 47.42x to 7.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | Rs11.61 | Rs550.65 | x |
| 2021-03-31 | Rs19.59 | Rs550.65 | x |
| 2022-03-31 | Rs30.07 | Rs550.65 | x |
| 2023-03-31 | Rs39.29 | Rs550.65 | x |
| 2024-03-31 | Rs48.73 | Rs550.65 | x |
| 2025-03-31 | Rs65.31 | Rs550.65 | x |
| 2026-03-31 | Rs78.42 | Rs550.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Blue Jet Healthcare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.22%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.16%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.21x
- Recent ROE (18.22%) is below the historical average (33.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 71.91% | 26.91% | 1.43x | 1.86x | Rs1.25 Billion |
| 2021 | 40.73% | 28.01% | 0.92x | 1.58x | Rs1.04 Billion |
| 2022 | 34.82% | 26.83% | 0.95x | 1.37x | Rs1.29 Billion |
| 2023 | 23.48% | 22.27% | 0.83x | 1.26x | Rs918.78 Million |
| 2024 | 19.37% | 23.05% | 0.67x | 1.25x | Rs792.29 Million |
| 2025 | 26.93% | 29.63% | 0.73x | 1.25x | Rs1.92 Billion |
| 2026 | 18.22% | 26.16% | 0.58x | 1.21x | Rs1.12 Billion |
Industry Comparison
This section compares Blue Jet Healthcare Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,959,856,571
- Average return on equity (ROE) among peers: 13.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Blue Jet Healthcare Limited (BLUEJET) | Rs13.60 Billion | 71.91% | 0.21x | $1.03 Billion |
| Concord Biotech Limited (CONCORDBIO) | $7.70 Billion | 21.96% | 0.22x | $1.67 Billion |
| Dishman Carbogen Amcis Limited (DCAL) | $53.79 Billion | 3.91% | 0.36x | $276.65 Million |
| Lyka Labs Limited (LYKALABS) | $457.59 Million | -12.13% | 3.75x | $31.36 Million |
| SMS Lifesciences India Limited (SMSLIFE) | $1.29 Billion | 10.49% | 1.34x | $42.13 Million |
| Supriya Lifescience Limited (SUPRIYA) | $6.16 Billion | 24.66% | 0.19x | $761.55 Million |
| Take Solutions Limited (TAKE) | $138.12 Million | 20.21% | 0.41x | $29.24 Million |
| Zota Health Care LImited (ZOTA) | $181.02 Million | 23.54% | 1.12x | $365.14 Million |
About Blue Jet Healthcare Limited
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance… Read more